Article Text

Download PDFPDF

Correction: Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

Statistics from Altmetric.com

Charles P, Terrier B, Perrodeau É, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann of Rheum Dis 2018;77:1143–9.

Table 1 has been corrected. The figures concerning ANCA-positivity rates at inclusion advertently inversed.

Table 1

General characteristics at inclusion

Also, the sentence in the Limitation section of the Discussion "Fixed-schedule infusion-arm patients were more likely to be ANCA-positive at inclusion." should read "Fixed-schedule infusion-arm patients were less likely to be ANCA-positive at inclusion."

View Abstract

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles